FDA reverses itself under pressure, moves to limit use of new Alzheimer’s drug

The Food and Drug Administration says the change is intended to address confusion among physicians and patients about who should get Aduhelm, which has faced an intense public backlash since its approval last month.

Commentary: Medicare must study unproven, expensive Alzheimer’s drug

Taxpayers and patients cannot afford to pay a high price for a treatment not known to be effective.

Controversial new Alzheimer’s drug gives patients in Maine hope

The treatment developed by Biogen could slow its progression, but health professionals and researchers are divided on whether the FDA was right to approve it.

FDA approves new drug for Alzheimer’s that experts doubt will work

The decision is sure to spark disagreements among doctors, medical researchers and patient groups, and have far-reaching implications for the standards used to evaluate experimental therapies.

Midcoast respite care center to open new location after closing amid pandemic

The nonprofit provides activities for people with dementia and Alzheimer's disease and resources such as support groups, community education and one-on-one counseling for caretakers.

Maine CDC reports 71 new coronavirus cases as outbreak hits Cape Elizabeth memory care home

The additional cases and 2 deaths come at a time when the Mills administration is relaxing restrictions on businesses to begin reviving Maine's economy.

Drugs fail to slow effects of inherited Alzheimer’s disease

Two experimental drugs have failed to prevent or slow mental decline in a study of people who are virtually destined to develop the disease because of rare gene flaws.

Alzheimer’s disease threatens an aging Maine

With the number of Mainers with Alzheimer's rising rapidly, research at The Jackson Lab and beyond is crucial to slowing its impact on families and taxpayers.

Minot woman gets ride to remember

Our View: Maine study part of effort to solve Alzheimer’s puzzle

Finding a cure has never been more important.